DK4054584T3 - Methods of treatment and/or prevention of major adverse cardiovascular events (MACE) with a combination of a BET bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor - Google Patents

Methods of treatment and/or prevention of major adverse cardiovascular events (MACE) with a combination of a BET bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor

Info

Publication number
DK4054584T3
DK4054584T3 DK20884269.0T DK20884269T DK4054584T3 DK 4054584 T3 DK4054584 T3 DK 4054584T3 DK 20884269 T DK20884269 T DK 20884269T DK 4054584 T3 DK4054584 T3 DK 4054584T3
Authority
DK
Denmark
Prior art keywords
inhibitor
mace
prevention
treatment
methods
Prior art date
Application number
DK20884269.0T
Other languages
Danish (da)
English (en)
Inventor
Christopher Ross Armstrong Halliday
Aziz Naeem Khan
Kenneth Eugene Lebioda
Original Assignee
Resverlogix Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Resverlogix Corp filed Critical Resverlogix Corp
Application granted granted Critical
Publication of DK4054584T3 publication Critical patent/DK4054584T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
DK20884269.0T 2019-11-05 2020-11-04 Methods of treatment and/or prevention of major adverse cardiovascular events (MACE) with a combination of a BET bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor DK4054584T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962930860P 2019-11-05 2019-11-05
PCT/IB2020/000912 WO2021090061A1 (en) 2019-11-05 2020-11-04 Methods of treatment and/or prevention of major adverse cardiovascular events (mace) with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor

Publications (1)

Publication Number Publication Date
DK4054584T3 true DK4054584T3 (en) 2025-09-01

Family

ID=75849803

Family Applications (1)

Application Number Title Priority Date Filing Date
DK20884269.0T DK4054584T3 (en) 2019-11-05 2020-11-04 Methods of treatment and/or prevention of major adverse cardiovascular events (MACE) with a combination of a BET bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor

Country Status (18)

Country Link
US (1) US12551484B2 (https=)
EP (1) EP4054584B1 (https=)
JP (1) JP7502811B2 (https=)
KR (1) KR102935008B1 (https=)
CN (1) CN114650824A (https=)
AU (1) AU2020377539B2 (https=)
BR (1) BR112022008223A2 (https=)
CA (1) CA3160147A1 (https=)
DK (1) DK4054584T3 (https=)
ES (1) ES3042146T3 (https=)
FI (1) FI4054584T3 (https=)
HU (1) HUE073043T2 (https=)
IL (1) IL292696B1 (https=)
MX (1) MX2022005029A (https=)
PL (1) PL4054584T3 (https=)
PT (1) PT4054584T (https=)
TW (1) TWI867086B (https=)
WO (1) WO2021090061A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114650824A (zh) 2019-11-05 2022-06-21 雷斯韦洛吉克斯公司 用bet溴结构域抑制剂和钠依赖性葡萄糖转运蛋白2抑制剂的组合治疗和/或预防主要不良心血管事件(mace)的方法
US20230398137A1 (en) * 2020-10-30 2023-12-14 Resverlogix Corp. Methods for lowering hba1c level with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor
US20220370485A1 (en) * 2021-01-14 2022-11-24 Lexicon Pharmaceuticals, Inc. Compounds and methods for treating or preventing cardiovascular diseases and conditions

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8410109B2 (en) 2005-07-29 2013-04-02 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
PT2118074E (pt) 2007-02-01 2014-03-20 Resverlogix Corp Compostos para a prevenção e tratamento de doenças cardiovasculares
SI2346837T1 (sl) 2008-06-26 2015-05-29 Resverlogix Corporation Postopki pripravljanja kinazolinonskih derivatov
KR101913109B1 (ko) 2009-03-18 2018-10-31 리스버로직스 코퍼레이션 신규한 소염제
MX2011009852A (es) 2009-03-27 2011-09-29 Bristol Myers Squibb Co Metodos para prevenir episodios cardiovasculares adversos mayores con inhibidores de dipeptidil peptidasa iv.
US9757368B2 (en) 2009-04-22 2017-09-12 Resverlogix Corp. Anti-inflammatory agents
JP2012528170A (ja) 2009-05-27 2012-11-12 ブリストル−マイヤーズ スクイブ カンパニー 別の抗糖尿病薬を用いた先の治療に抵抗性を有する２型糖尿病患者をｓｇｌｔ２阻害剤およびその組成物を用いて治療する方法
CA2851996C (en) 2011-11-01 2020-01-07 Resverlogix Corp. Pharmaceutical compositions for substituted quinazolinones
US20130281398A1 (en) 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
EP4678242A3 (en) 2013-04-18 2026-03-18 Boehringer Ingelheim International GmbH Pharmaceutical composition, methods for treating and uses thereof
HK1219434A1 (zh) * 2013-08-21 2017-04-07 Resverlogix Corp. 用於加速斑块消退的组合物和治疗方法
AU2014310371A1 (en) 2013-08-21 2016-03-10 Resverlogix Corp. Compositions and therapeutic methods for accelerated plaque regression
TW201625605A (zh) * 2014-04-04 2016-07-16 賽諾菲公司 用於治療糖尿病、肥胖、血脂異常及相關病症之作為ｇｐｒ１１９調節劑的經取代之稠合雜環類
US10111885B2 (en) 2015-03-13 2018-10-30 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
EP3355922A2 (en) * 2015-10-02 2018-08-08 Dana Farber Cancer Institute, Inc. Combination therapy of bromodomain inhibitors and checkpoint blockade
EP3553058A1 (en) 2016-12-09 2019-10-16 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal form of bromodomain protein inhibitor drug, preparation method and use thereof
US11419883B2 (en) 2017-05-05 2022-08-23 The Regents Of The University Of California Inhibiting senescent processes in beta cells for the prevention of type 1 diabetes
CN114650824A (zh) 2019-11-05 2022-06-21 雷斯韦洛吉克斯公司 用bet溴结构域抑制剂和钠依赖性葡萄糖转运蛋白2抑制剂的组合治疗和/或预防主要不良心血管事件(mace)的方法
JP7763761B2 (ja) 2020-01-08 2025-11-04 レスバーロジックス コーポレイション Ｂｅｔブロモドメイン阻害剤およびジペプチジルペプチダーゼ４阻害剤の組合せによる主要有害心血管イベント（ｍａｃｅ）の治療方法および／または予防方法
US20230398137A1 (en) * 2020-10-30 2023-12-14 Resverlogix Corp. Methods for lowering hba1c level with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor
CA3197706A1 (en) 2020-10-30 2022-05-05 Resverlogix Corp. Methods for improving renal function with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor

Also Published As

Publication number Publication date
KR20220098757A (ko) 2022-07-12
IL292696B1 (en) 2026-01-01
EP4054584B1 (en) 2025-07-09
IL292696A (en) 2022-07-01
US20220370452A1 (en) 2022-11-24
BR112022008223A2 (pt) 2022-09-06
HUE073043T2 (hu) 2025-12-28
MX2022005029A (es) 2022-07-12
TW202131924A (zh) 2021-09-01
AU2020377539A1 (en) 2022-05-19
CN114650824A (zh) 2022-06-21
ES3042146T3 (en) 2025-11-18
FI4054584T3 (fi) 2025-08-22
CA3160147A1 (en) 2021-05-14
TWI867086B (zh) 2024-12-21
EP4054584A4 (en) 2023-11-08
EP4054584A1 (en) 2022-09-14
KR102935008B1 (ko) 2026-03-09
PT4054584T (pt) 2025-07-16
AU2020377539B2 (en) 2025-05-29
JP2023500685A (ja) 2023-01-10
PL4054584T3 (pl) 2025-11-03
WO2021090061A1 (en) 2021-05-14
US12551484B2 (en) 2026-02-17
JP7502811B2 (ja) 2024-06-19

Similar Documents

Publication Publication Date Title
DK4054584T3 (en) Methods of treatment and/or prevention of major adverse cardiovascular events (MACE) with a combination of a BET bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor
ES3063562T3 (en) Combination therapy including a kras-g12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
IL283598A (en) Combined treatment with radio-immune conjugates and a checkpoint inhibitor
EP4469449A4 (en) PARP1 INHIBITORS AND THEIR USES
IL320829A (en) PARP1 inhibitors and their uses
IL280591A (en) Methods for delaying the onset of new type 2 diabetes and slowing the progression and treatment of type 2 diabetes
PL4094763T3 (pl) Związek do stosowania w zapobieganiu i/lub leczeniu stanu wywołanego lub związanego z koronawirusem
SG11202107720UA (en) Cnx/erp57 inhibitor for use in the treatment or prevention of cancer
IL275925A (en) Prevention and treatment of organ damage
ZA202202617B (en) Treatment of cancer using a combination comprising multi-tyrosine kinase inhibitor and immune checkpoint inhibitor
IL294344B1 (en) Methods for treating and/or preventing major cardiovascular events (MACE) with a combination of a BET bromodomain inhibitor and a dipeptidyl peptidase 4 inhibitor
IL309243A (en) Radioimmunoconjugates and combination therapy with barrier surveillance
GB202103578D0 (en) Prevention and treatment of infections including those caused by coronavirus
PL4069278T3 (pl) Sposoby i kompozycje do zapobiegania cukrzycy typu 1
HK40076178A (en) Methods of treatment and/or prevention of major adverse cardiovascular events (mace) with a combination of a bet bromodomain inhibitor and a dipeptidyl peptidase 4 inhibitor
EP4178359A4 (en) COMBINATION THERAPIES FOR THE TREATMENT AND PREVENTION OF BIOFILMS
HUE059233T2 (hu) Vegyület epizootius nyúl-enteropátia kezelésében és/vagy megelõzésében való alkalmazásra
GB2625512B (en) Triggered-producer and triggered-consumer instructions
PL4061399T3 (pl) Działanie insulinotropowe i glukagonotropowe beta-laktoglobuliny
IL321017A (en) Inhibitors and/or decomposers containing 3-fluoro-4-hydroxybenzmide and uses thereof
HK40113727A (en) Methods for the prevention and treatment of synucleinopathies
GB202210704D0 (en) Biofilm prevention and treatment
HK40109325A (en) Radioimmunoconjugates and checkpoint inhibitor combination therapy
AU2025203707A1 (en) Methods of inhibiting MASP-2 for the treatment and/or prevention of coronavirus-induced acute respiratory distress syndrome
HK40087806A (en) Combination therapies for the treatment and prevention of biofilms